Exploring Adjuvant Immunotherapy In Hcc And Risk Stratification Challenges
Exploring Adjuvant Immunotherapy In Hcc And Risk Stratification Challenges reveals several interesting facts.
- In this video you will learn how to assess liver function in patients with
- Dr. Kaseb, Professor, The University of Texas M.D. Anderson Cancer Center, explains the role of
- Ahmed Omar Kaseb, MD, associate professor of Gastrointestinal Medical Oncology at The University of Texas MD Anderson ...
- Catherine T. Frenette, MD, and Darren S. Sigal, MD, discuss when it is the right time to move to systemic therapy for a
- Anthony El-Khoueiry, MD, reviews the evidence for
In-Depth Information on Adjuvant Immunotherapy In Hcc And Risk Stratification Challenges
Stephen Lam Chan, MD, FRCP, Chinese University of Hong Kong, Hong Kong, China, discusses the findings of recent studies in ... Laura W. Goff, MD, Vanderbilt-Ingram Cancer Center, shares how she chooses between atezolizumab plus bevacizumab and ... Dina Ioffe, MD, Fox Chase Cancer Center, discusses using Dr. Mark Yarchoan from Johns Hopkins University presents on
Pierce Chow, MBBS, MMed (Surg), FRCS (Edin), FAMS (Gen Surg), PhD, National Cancer Centre Singapore & Duke-NUS ...
Stay tuned for more updates related to Adjuvant Immunotherapy In Hcc And Risk Stratification Challenges.